Genmab — Januar 2014
-
-
Dette ser stærkt ud (ofatumumab i ALL): With a median follow up of 8 months (1-23), 18 pts are alive and in CR; 1 pt has undergone an allogeneic stem cell transplant after cycle 3 by reason of a highly complex karyotype at diagnosis. The 1-year CRD and overall survival rates were 100% and 95% respectively.
-
-
Og denne:Pts with CLL who have early stage disease (Rai 0-II) but have high-risk prognostic markers such as deletion 17p or deletion 11q have an increased risk of disease progression. Currently, these pts are offered watch-and-wait approach. The objective of this Phase II study is to evaluate the efficacy of ofatumumab in treating these pts with the goal to delay time to first chemoimmunotherapy treatment
-
-
Mere endnu: Conclusions The O-dex regimen shows relatively high ORR and CR, with promising findings for PFS and OS (including pts. harboring p53 defects), as compared to published data on rituximab plus dexamethasone regimen or ofatumumab in monotherapy.
-
-
sorgløs... hmmm...
-
ja, på dage som disse her i 2014 glemmer man lidt at det ikke altid er sorgløst at være GEN'er
-
well - og så alligevel ikke. Det er sgu da lidt af en reversal GEN laver på en positiv dag. Forhåbentlig ikke dårlige nyheder på vej...
-
wouw - her er forklaringen - Pharmacyclics Inc. (PCYC: Quote) announced Tuesday morning that an Independent Data Monitoring Committee unanimously recommended that the Phase III RESONATE study, PCYC-1112-CA, a head-to-head comparison of IMBRUVICATM versus ofatumumab, be stopped early because the primary and a key secondary endpoint of the study have been met
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind